DeepMed Research

The Case Comprehensive Cancer Center

🇺🇸United States

Country: 🇺🇸United States

Ownership: Subsidiary

Established: 1826-01-01

Employees: 5K

Market Cap: -

Website: http://www.case.edu/cancer

Clinical Trials

Nivolumab in Combination With Talazoparib in Melanoma and Mutations in BRCA or BRCA-ness Genes

Phase 2

Completed

Conditions: Metastatic or Unresectable Melanoma

Interventions: Drug: Nivolumab
Drug: Talazoparib

First Posted Date: 2019-12-05

Last Posted Date: 2025-01-14

Lead Sponsor: Case Comprehensive Cancer Center

Target Recruit Count: 8

Registration Number: NCT04187833

Locations: 🇺🇸
Cleveland Clinic Taussig Cancer institute, Case Comprehensive Cancer Center, Cleveland, Ohio, United States

Perioperative Analgesia on Postoperative Opioid Usage and Pain Control in H&N Cancer Surgery

Phase 3

Terminated

Conditions: Postoperative Pain Control
Opioid Consumption

Interventions: Drug: Placebo Ketamine
Drug: Ketamine
Drug: Placebo Lidocaine
Drug: Lidocaine
Drug: Placebo Acetaminophen
Drug: Acetaminophen
Drug: Placebo Gabapentin
Drug: Gabapentin
Drug: Placebo Celecoxib
Drug: Celecoxib

First Posted Date: 2019-11-25

Last Posted Date: 2024-11-12

Lead Sponsor: Case Comprehensive Cancer Center

Target Recruit Count: 30

Registration Number: NCT04176419

Locations: 🇺🇸
Cleveland Clinic Taussig Cancer institute, Case Comprehensive Cancer Center, Cleveland, Ohio, United States

Vitamin D Supplementation as a Neoadjuvant for Photodynamic Therapy of Actinic Keratoses

Phase 2

Completed

Conditions: Actinic Keratosis

Interventions: Drug: Photodynamic therapy (PDT)
Drug: Vitamin D3

First Posted Date: 2019-10-25

Last Posted Date: 2022-06-24

Lead Sponsor: Case Comprehensive Cancer Center

Target Recruit Count: 75

Registration Number: NCT04140292

Locations: 🇺🇸
Cleveland Clinic Taussig Cancer institute, Case Comprehensive Cancer Center, Cleveland, Ohio, United States

Building Family Caregiver Skills Using a Simulation-Based Intervention for Care of Cancer Patients

Not Applicable

Active, not recruiting

Conditions: Cancer

Interventions: Behavioral: One-on-one teaching sessions
Behavioral: Telephone booster contact

First Posted Date: 2019-08-14

Last Posted Date: 2025-05-13

Lead Sponsor: Case Comprehensive Cancer Center

Target Recruit Count: 488

Registration Number: NCT04055948

Locations: 🇺🇸
University Hospitals Cleveland Medical Center, Case Comprehensive Cancer Center, Cleveland, Ohio, United States
🇺🇸
MetroHealth Medical Center, Cleveland, Ohio, United States

Regorafenib in Bevacizumab Refractory Recurrent Glioblastoma

Phase 2

Active, not recruiting

Conditions: Recurrent Glioblastoma

Interventions: Drug: Regorafenib

First Posted Date: 2019-08-09

Last Posted Date: 2024-12-05

Lead Sponsor: Case Comprehensive Cancer Center

Target Recruit Count: 14

Registration Number: NCT04051606

Locations: 🇺🇸
Cleveland Clinic Taussig Cancer institute, Case Comprehensive Cancer Center, Cleveland, Ohio, United States

Targeted Therapy With CDK4/6 Inhibitors in Chemo-Refractory, Rb Wild-Type Extensive SCLC

Phase 2

Recruiting

Conditions: Small-cell Lung Cancer
Large Cell Neuroendocrine Carcinoma of the Lung
Extrapulmonary Small Cell Carcinoma

Interventions: Drug: Abemaciclib,

First Posted Date: 2019-07-08

Last Posted Date: 2025-03-26

Lead Sponsor: Case Comprehensive Cancer Center

Target Recruit Count: 29

Registration Number: NCT04010357

Locations: 🇺🇸
Case Medical Center, University Hospitals Seidman Cancer Center, Case Comprehensive Cancer Center, Cleveland, Ohio, United States

Innovations to Prevent Relapse Among Low-income African American Smokers

Not Applicable

Completed

Conditions: Smoking Cessation

Interventions: Other: Nicotine replacement therapy (NRT)
Behavioral: CS-CBT intervention
Behavioral: Relapse prevention program
Behavioral: Path2Quit
Behavioral: SmokefreeTXT

First Posted Date: 2019-06-11

Last Posted Date: 2021-11-04

Lead Sponsor: Case Comprehensive Cancer Center

Target Recruit Count: 18

Registration Number: NCT03982576

Locations: 🇺🇸
Case Western Reserve University, Case Comprehensive Cancer Center, Cleveland, Ohio, United States

CPX-351 Therapy for MDS After Hypomethylating Agent Failure

Phase 2

Terminated

Conditions: Myelodysplastic Syndrome (MDS)

Interventions: Drug: CPX-351

First Posted Date: 2019-05-21

Last Posted Date: 2024-08-15

Lead Sponsor: Case Comprehensive Cancer Center

Target Recruit Count: 4

Registration Number: NCT03957876

Locations: 🇺🇸
Cleveland Clinic Taussig Cancer institute, Case Comprehensive Cancer Center, Cleveland, Ohio, United States

Free Flap Breast Reconstruction Using Virtual Surgical Planning and 3-D Modeling

Not Applicable

Terminated

Conditions: Breast Reconstruction

Interventions: Procedure: 3D medical models

First Posted Date: 2019-05-14

Last Posted Date: 2024-02-07

Lead Sponsor: Case Comprehensive Cancer Center

Target Recruit Count: 38

Registration Number: NCT03949491

Locations: 🇺🇸
Cleveland Clinic, Case Comprehensive Cancer Center, Cleveland, Ohio, United States

18F-Fluciclovine PET to Distinguish Tumor Progression From Radiation Necrosis

Early Phase 1

Completed

Conditions: Secondary Malignant Neoplasm of Brain and Cerebral Meninges

Interventions: Drug: 18F-fluciclovine
Device: PET/CT of the brain

First Posted Date: 2019-04-29

Last Posted Date: 2021-05-05

Lead Sponsor: Case Comprehensive Cancer Center

Target Recruit Count: 18

Registration Number: NCT03930173

Locations: 🇺🇸
Cleveland Clinic Taussig Cancer institute, Case Comprehensive Cancer Center, Cleveland, Ohio, United States

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy